US 7208289
Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 protein
granted A61KA61K38/1709
Quick answer
US patent 7208289 (Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 protein) held by Rigel Pharmaceuticals, Inc. expires Mon Apr 19 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Apr 24 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 19 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61K, A61K38/1709